These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 8614850)

  • 1. Implications of the new biology for therapy in breast cancer.
    Sledge GW
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):76-81. PubMed ID: 8614850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New concepts in breast cancer therapy.
    Snyder RD
    Intern Med J; 2004 May; 34(5):266-9. PubMed ID: 15151673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies.
    Pluda JM
    Semin Oncol; 1997 Apr; 24(2):203-18. PubMed ID: 9129690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative breast cancer: role of antiangiogenic agents.
    Greenberg S; Rugo HS
    Cancer J; 2010; 16(1):33-8. PubMed ID: 20164688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
    Zucker S; Cao J; Chen WT
    Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Goal of Cancer Treatment.
    Balis FM
    Oncologist; 1998; 3(4):V. PubMed ID: 10388118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological therapy of breast cancer: recent clinical applications.
    Baar J
    Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beware the Medical-Industrial Complex.
    Stevens CW; Glatstein E
    Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis.
    de Jong JS; van Diest PJ; van der Valk P; Baak JP
    J Pathol; 1998 Jan; 184(1):53-7. PubMed ID: 9582527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):1-4. PubMed ID: 10203263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review).
    Wu J
    Anticancer Res; 1996; 16(4B):2233-9. PubMed ID: 8694549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical perspective of angiogenesis inhibitors].
    Radema SA; Witteveen PO; Gebbink MB; Voest EE
    Ned Tijdschr Geneeskd; 2003 Aug; 147(35):1675-80. PubMed ID: 14513538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A; Folkman J
    Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.